INTRODUCTION {#S0001}
============

Thalassemia is a common genetic disorder with autosomal recessive inheritance in the world, and is associated with clinical symptoms of hemolytic anemia.^[@CIT0001],\ [@CIT0002]^ This disease has a high incidence in various parts of Iran, such as the Caspian region, Persian Gulf margin and Fars and Isfahan provinces.^[@CIT0003]--[@CIT0005]^ Similar to other genetic disorders of recessive inheritance, the importance of β-thalassemia is due to heterozygote individuals carrying a mutant haplotype without specific clinical symptoms. Following the marriage of two heterozygous individuals for β-thalassemia (thalassemia minor patients), there is 25% chance of homozygous patients, 50% chance of heterozygous birth carrying the disease gene, and 25% chance of birth of a healthy homozygous individual.^[@CIT0006]--[@CIT0009]^ DNA assay can be used for definitive diagnosis of thalassemia. Molecular genetic tests are facilitated because of presumed incidence of a few mutations in any given population. However, molecular genetic methods may not be substituted for biochemical and hematological testing.^[@CIT0006],\ [@CIT0010],\ [@CIT0011]^Since prenatal diagnosis (PND) is important in many genetic disorders such as hemoglobinopathies, proper DNA isolation and analysis during fetal period is further emphasized. The first trimester of pregnancy (10-12 weeks) is optimum for DNA extraction from chorionic villi (CVS).^[@CIT0006],\ [@CIT0012]--[@CIT0014]^

MATERIALS AND METHODS {#S0002}
=====================

In this study, 316 fetal samples (including amniotic fluid or CVS) from carrier couples for thalassemia or hemoglobinopathy were subject to molecular testing. DNA extractions from these samples were conducted using Bioneer kit (S. Korea). Identification test of the fetus was compared with parent samples to ensure no contamination of the fetal sample with maternal tissues and to properly authenticate the fetus. Due to diversity of common mutations in Khuzestan and the time limit for review of fetal samples, the first step in determining the mutation was sequencing the β-globin gene as two separate segments. The first segment comprising -110 upstream nucleotides of the gene up until the first part of the second intron was amplified and sequenced using forward 5\'AACTCCTAAGCCAGTGCCAGAAGA3' and reverse 5\'CCCCTTCCTATGACATGAACTTAA3' primers. The second segment of the gene contains the final part of the second intron up to downstream of the gene, amplified and sequenced using primer pair of forward 5\'CAATGTATCATGCCTCTTTGCACC3 'and reverse 5\'CACTGACCTCCCACATTCCCTTTT3'. PCR mixture contained 100ng patient DNA, 2.5µL 10X PCR buffer, 1.5 mMMg Cl2, 0.2 mM dNTP,0.4 pmol/L of each of the primers, reaching the final concentration of µL using water free from RNase and DNase. PCR program was as follows: 3 minutes in 95°^C^, 30 temperature cycles consisting of 30 seconds in 95°^C^, 30 seconds in 59°^C^, 30 seconds in 72°^C^ and finally 5 minutes of incubation at 72°^C^. After sequencing, for final confirmation and ensuring the absence of gene deletion or amplification, RFLP Linkage and ARMS were performed in the same PCR conditions, with the primers and enzymes used listed in [Tables 1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"}. RFLP has also been used in hemoglobinopathy for diagnosis of Hb Sand HbD.^[@CIT0023]^ In all cases, negative control containing all the materials except for patient DNA was used to ensure lack of contamination. In addition, reverse dot blot (RDB) kit (Vienna lab. Austria) was used to detect mutations or deletions not detectable using current sequencing and PCR methods, such as -619 bp Del mutation.

###### 

Primers Used in ARMS Method to Evaluate β-globin Gene^[@CIT0023]^

  (Fragment Length) bp   Second Primer   (sequence )5' \> 3'               First Primer
  ---------------------- --------------- --------------------------------- --------------------------
  **684**                **A**           TCACTTAGACCTCACCCTGTGGAGCCTCAT    --88 (C \> T) mutant
                                         CACTTAGACCTCACCCTGTGGAGCCACCCCA   --88 (C \> T) normal
  **520**                **A**           ACACCATGGTGCACCTGACTCCTGAGCAGG    CD8 (--AA) mutant
                                         ACACCATGGTGCACCTGACTCCTGAGCAGA    CD8 (--AA) normal
  **225**                **B**           CCTTGCCCCACAGGGCAGTAACGGCACACC    CD8/9 (+G) mutant
                                         CCTTGCCCCACAGGGCAGTAACGGCACACT    CD8/9 (+G) normal
  **439**                **B**           GAGTGGACAGATCCCCAAAGGACTCAACCT    CD41/42 (--TCTT) mutant
                                         GAGTGGACAGATCCCCAAAGGACTCAAAGA    CD41/42 (--TCTT) normal
  **281**                **B**           TTAAACCTGTCTTGTAACCTTGATACCGAT    IVS1-1 (G \> A) mutant
                                         TTAAACCTGTCTTGTAACCTTGATACCCAC    IVS1-1 (G \> A) normal
  **285**                **B**           CTCCTTAAACCTGTCTTGTAACCTTGTTAG    IVS1-5 (G \> C) mutant
                                         CTCCTTAAACCTGTCTTGTAACCTTGTTAC    IVS1-5 (G \> C) normal
  **286**                **B**           TCTCCTTAAACCTGTCTTGTAACCTTCATG    IVS1-6 (T \> C) mutant
  **449**                **A**           AGTTGGTGGTGAGGCCCTGGGCAGGTTGGT    IVS1-6 (T \> C) normal
  **419**                **B**           ACCAGCAGCCTAAGGGTGGGAAAATAGAGT    IVS1-110 (G \> A) mutant
                                         ACCAGCAGCCTAAGGGTGGGAAAATACACC    IVS1-110 (G \> A) normal
  **634**                **B**           AAGAAAACATCAAGGGTCCCATAGACTGAT    IVS2-1 (G \> A) mutant
                                         AAGAAAACATCAAGGGTCCCATAGACTGAC    IVS2-1 (G \> A) normal
  **738**                **D**           TCATATTGCTAATAGCAGCTACAATCGAGG    IVS2-745 (C \> G) mutant
                                         TCATATTGCTAATAGCAGCTACAATCGAGC    IVS2-745 (C \> G) normal
                                         CCCCTTCCTATGACATGAACTTAA          A
                                         ACCTCACCCTGTGGAGCCAC              B
                                         TTCGTCTGTTTCCCATTCTAAACT          C
                                         GAGTCAAGGCTGAGAGATGCAGGA          D

###### 

Linkage RFLP of β-globin Gene^[@CIT0023]^

  RFLP Product Size in case of lack of enzymatic excision site   RFLP Product Size in case of presence of enzymatic excision site   PCR Product Size   Enzymes and Primer sequence
  -------------------------------------------------------------- ------------------------------------------------------------------ ------------------ --------------------------------
  760                                                            315                                                                760                Hind II/ɛ
                                                                 445                                                                                   5\'TCTCTGTTTGATGACAAATTC
                                                                                                                                                       5\'AGTCATTGGTCAAGGCTGACC
  326                                                            235                                                                326                Hind III/Gγ
                                                                 91                                                                                    5\'AGTGCTGCAAGAAGAACAACTACC
                                                                                                                                                       5\'CTCTGCATCATGGGCAGTGAGCTC
  635                                                            327                                                                635                Hind III/Aγ
                                                                 308                                                                                   5\'ATGCTGCTAATGCTTCATTAC
                                                                                                                                                       5\'TCATGTGTGATCTCTCAGCAG
  795                                                            691                                                                795                Hind II/5'ψβ
                                                                 104                                                                                   5\'TCCTATCCATTACTGTTCCTTGAA
                                                                                                                                                       5\'ATTGTCTTATTCTAGAGACGATTT
  795                                                            440                                                                795                Ava II/ψβ
                                                                 355                                                                                   Hind II/5'ψβ RFLP Primer
  913                                                            479                                                                913                Hind II/3'ψβ
                                                                 434                                                                                   5\'GTACTCATACTTTAAGTCCTAACT
                                                                                                                                                       5\'TAAGCAAGATTATTTCTGGTCTCT
  411                                                            330                                                                1200               Rsa I/β
  694                                                            81                                                                                    5\'AGACATAATTTATTAGCATGCATG
  695                                                            694                                                                                   5\'CCCCTTCCTATGACATGAACTTAA
  320                                                            213                                                                474                Hinf I/β
  154                                                            107                                                                                   5\'GGAGGTTAAAGTTTTGCTATGCTGTAT
                                                                 154                                                                                   5\'GGGCCTATGATAGGGTAAT
  328                                                            228                                                                328                Ava II/β
                                                                 100                                                                                   5\'GTGGTCTACCCTTGGACCCAGAGG
                                                                                                                                                       5\'TTCGTCTGTTTCCCATTCTAAACT

RESULTS {#S0003}
=======

There were a total of 316 fetal samples. It should be noted that all the samples came from families native to Khuzestan Province. PND indicated 11.7% incidence of sickle cell (HbS) mutation, 1.2% incidence of concomitant HbS and β-thalassemia mutation, 0.3% incidence of HbD mutation and 56.8% incidence of at least one of β-thalassemia mutations. The fetus was healthy in 23.4% of the patients, and 6.6% of the patients were excluded from the study for various reasons. The results were indicative of 13.9% and 10.1% incidence of at least CD 36-37 (-T) and IVS II-1 (G \> A) polymorphisms in the population under study, respectively. These mutations had the highest incidence in samples subject to PND. Our findings also suggested 0.5% incidence of combined HbS and β-thalassemiain patients. [Table 3](#T0003){ref-type="table"} shows the number and incidence of each mutation in the population under study.

###### 

Evaluation of Mutations, Their Number and Incidence in β-globin Gene, and the Prevalence of β-globin Gene in the Studied Population

  --------------------------------------- -------- ----------------
  β-globin gene mutation                  number   Incidence rate
  Alpha thalassemia carriers              21       6.6
  -28(A \> C)                             2        0.6
  -88(C \> A)                             3        0.9
  -88(C \> A)/IVS II-1 (G \> A)           3        0.9
  +20 with IVS II 745 (                   1        0.3
  CD 22-24                                2        0.6
  CD 30 (G \> C)                          1        0.3
  CD 36-37 (- T)                          33       10.4
  CD 36-37 (- T)/ CD 36-37 (- T)          9        2.8
  CD 36-37 (- T)/ CD 82-83 (-G)           1        0.3
  CD 36-37 (- T)/IVS I-110 (G \> A)       1        0.3
  CD 45\[-T\]                             1        0.3
  CD 5\[-CT\]                             5        1.6
  CD 6(HbS)                               28       8.9
  CD 6(HbS)/ CD 6(HbS)                    9        2.8
  CD 6(HbS)/IVS I (-25nt)                 1        0.3
  CD 8 (-AA)                              8        2.5
  CD 8 (-AA)/ CD 8 (-AA)                  5        1.6
  CD 8-9 (+G)                             3        0.9
  CD 8-9 (+G)/ CD 8-9 (+G)                1        0.3
  CD8-9 (+G)/ CD 82-83 (-G)               1        0.3
  CD 82-83 (-G)                           1        0.3
  CD 82-83 (-G)/ CD 82-83 (-G)            1        0.3
  CD 39 (C \> T)                          2        0.6
  CD 39 (C \> T)/ CD 39 (C \> T)          1        0.3
  CD 39 (C \> T)/IVSI-6 (T \> C)          1        0.3
  CD 44(-C)                               2        0.6
  CD 44(-C)/-80                           1        0.3
  CD 44(-C)/ CD 22-24                     1        0.3
  CD 44(-C)/ CD 44(-C)                    1        0.3
  CD 8 (-AA)/IVS I-110 (G \> A)           1        0.3
  HbD                                     1        0.3
  initCD(T \> C)                          3        0.9
  IVS I (-25nt)                           7        2.2
  IVS I (-25nt)/ CD 6 (A \> T)(HbS)       1        0.3
  IVS I (-25nt)/ CD 82-83 (-G)            1        0.3
  IVS I (-25nt)/IVS I (-25nt)             1        0.3
  IVS I-1 (G \> A)                        6        1.9
  IVS I-1 (G \> A)/ CD 6(HbS)             1        0.3
  IVS I-1 (G \> A)/IVS I-1 (G \> A)       1        0.3
  IVS I-1 (G \> A)/IVSI-128(T \> G)       1        0.3
  IVS I-110 (G \> A)                      11       3.5
  IVS I-110 (G \> A)/ CD 36-37 (- T)      1        0.3
  IVS I-110 (G \> A)/ CD 8 (-AA)          1        .3
  IVS I-110 (G \> A)/IVS I-110 (G \> A)   5        1.6
  IVS I-5 (G \> C)                        7        2.2
  IVS I-5 (G \> C)/-619bp del             1        0.3
  IVS I-5 (G \> C)/IVS I-5 (G \> C)       4        1.3
  IVS II-1 (G \> A)                       20       6.3
  IVS II-1 (G \> A)/ CD 8-9 (+G)          1        0.3
  IVS II-1 (G \> A)/IVS I-110 (G \> A)    1        0.3
  IVS II-1 (G \> A)/IVS II-1 (G \> A)     7        2.2
  IVSI- 17 pb                             1        0.3
  IVSI-128(T \> G)                        2        0.6
  IVSI-128(T \> G)/IVSI-128(T \> G)       1        0.3
  IVSI-5(G \> C)/ CD 6(HbS)               1        0.3
  IVSI-6 (T \> C)                         3        0.9
  IVSI-6 (T \> C)/IVSI-6 (T \> C)         1        0.3
  Normal                                  74       23.4
  Total                                   316      100.0
  --------------------------------------- -------- ----------------

DISCUSSION {#S0004}
==========

Since hemoglobinopathy disorders cause social and economic problems in healthcare system of our country, detection of the type of β-globin gene mutations in PND samples is important due to correlation between gene polymorphism and clinical symptoms. However, the relationship between genotype and phenotype in patients with hemoglobinopathy is not straightforward.^[@CIT0006],\ [@CIT0016],\ [@CIT0017]^ Indeed, detection of homozygous genotypes can partially reveal the clinical status of patients in terms of thalassemia major, thalassemia intermedia, sickle cell syndrome and other disease cases.^[@CIT0006],\ [@CIT0017]^ In heterozygous mutant forms, despite the absence of specific severe clinical findings, identifying the mutations involved can help assess disease risk in newborns. In fact, premarital screening of the couples and PND in the first trimester of pregnancy can help evaluate the risk of disease in newborn.^[@CIT0017]^ In this study, it was found that about 75% of newborns carry at least a mutant β-globin gene. 18% of PND samples possessed two β-thalassemia genes, indicating β-thalassemia major or intermedia in fetus, whose mothers were subject to abortion procedure. In another study conducted in 2007, it was found that 10.3% of pregnant women under study had fetuses affected by hemoglobinopathy, and the fetuses were eliminated by abortion. In this study, β-thalassemia was found to be the most prevalent hemoglobinopathy disorder with 55% incidence.^[@CIT0017]^ Due to significant increase in cases of β-thalassemia in Iran in recent years, lack of remarkable outcome from genetic counseling as well as public media in reducing this incidence has been noted by Rahim et al.^[@CIT0016]^ Other studies have indicated notable effect of various governmental and non-governmental organizations in public notification during premarital screening programs in reducing the incidence of these hereditary disorders in Cyprus, Italy, Canada and United Kingdom.^[@CIT0018]--[@CIT0022]^

In this study, CD 36-37 (-T) and IVS II-1 (G\> A) were the most prevalent β-thalassemia mutations with respective incidence of 13.9% and 10.4%. These findings are in agreement with another study conducted in Khuzestan Province.^[@CIT0016]^ Maleki et al., have only indicatedIVS II-1 (G\> A) as a prevalent mutation in Iran.^[@CIT0015]^ IVSI-6 (T\> C) mutation (Portuguese variant), a common Mediterranean mutation, has been recognized as the most common marker of mild β-thalassemia.^[@CIT0023]^ The highest incidence of this mutation has been found in Khuzestan and Shiraz provinces.^[@CIT0024]^ However, the incidence of this mutation in our study was 1.2%. In the study of Maleki et al., the prevalence of this mutation in Tehran in patients with β-thalassemia was 2.6%.^[@CIT0015]^ In another study, IVS I-5 (G\> C) mutation has been cited as the second most common β-thalassemia mutation in Iran, with higher prevalence in southern Iran than in northern region.^[@CIT0025]^ However, in this study, we found 4.1% prevalence of this marker in PND samples.

Genetic counseling and prenatal molecular diagnosis are effective in reducing the risk of hemoglobin disorders. In this regard, preventive strategies are significant, especially in parts of Iran with high prevalence of hemoglobin disorders like Ahvaz. In addition, incidence survey of common and rare mutations in these regions can help identify the carriers of hemoglobinopathy gene to prevent the birth of patients with acute symptoms of the disease.
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